| Dr Dhanunjaya Lakkireddy, MD | |
|
3901 Rainbow Blvd, Suite#g600, Kansas City, KS 66160-8500 | |
| (913) 588-9600 | |
| (913) 588-9770 |
| Full Name | Dr Dhanunjaya Lakkireddy |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 27 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023067881 | NPI | - | NPPES |
| 105678 | Other | KS | BCBS KS OUTREACH CLINICS |
| 200387770B | Medicaid | KS | |
| 200387770A | Medicaid | KS | |
| 203747605 | Medicaid | MO | |
| 37126012 | Other | MO | BCBS KC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overland Park Reg Med Ctr | Overland park, KS | Hospital |
| Menorah Medical Center | Overland park, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Heart And Vascular Specialists Llc | 7618122417 | 81 |
| Midwest Heart And Vascular Specialists Llc | 7618122417 | 81 |
News Archive
People who sustain a traumatic brain injury (TBI) are at high risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is a leading cause of death in these patients.
Slightly over 5 percent of the nearly 39 million Americans age 65 and older in 2007 reported one or more cognitive disorders, such as senility or dementia, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.
A paper published today by Science Translational Medicine outlines the process by which a category of anticancer drugs called curaxins inhibit tumor cell growth and division.
› Verified 1 days ago
| Entity Name | Midwest Heart & Vascular Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760736615 PECOS PAC ID: 7618122417 Enrollment ID: O20130228000218 |
News Archive
People who sustain a traumatic brain injury (TBI) are at high risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is a leading cause of death in these patients.
Slightly over 5 percent of the nearly 39 million Americans age 65 and older in 2007 reported one or more cognitive disorders, such as senility or dementia, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.
A paper published today by Science Translational Medicine outlines the process by which a category of anticancer drugs called curaxins inhibit tumor cell growth and division.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dhanunjaya Lakkireddy, MD 5501 Nw 62nd Ter, Suite 201, Kansas City, MO 64151-2411 Ph: (816) 584-8884 | Dr Dhanunjaya Lakkireddy, MD 3901 Rainbow Blvd, Suite#g600, Kansas City, KS 66160-8500 Ph: (913) 588-9600 |
News Archive
People who sustain a traumatic brain injury (TBI) are at high risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is a leading cause of death in these patients.
Slightly over 5 percent of the nearly 39 million Americans age 65 and older in 2007 reported one or more cognitive disorders, such as senility or dementia, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.
A paper published today by Science Translational Medicine outlines the process by which a category of anticancer drugs called curaxins inhibit tumor cell growth and division.
› Verified 1 days ago
Micholee Beth Polsak, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Kansas University Physicians Inc, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Ira William Marsh, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 8929 Parallel Pkwy, Kansas City, KS 66112 Phone: 913-596-4000 | |
Dr. Tara L Lin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6030 Fax: 913-588-4085 | |
Kristin N Fee, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 2027, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Donald J. Mcsweyn, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Suite 580, Kansas City, KS 66112 Phone: 913-596-7224 Fax: 913-596-7257 | |
Archana Pareek, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Division Of General And Geriatric Medicine, University, Kansas City, KS 66160 Phone: 913-588-6005 Fax: 913-588-3877 |